On the 23rd of March, Point72 Asset Management bought 1.3 million Tricida , Inc. (NASDAQ:TCDA) shares for $6.6 million at an average price of $5.01 per share. Shares of Tricida,...
On the 22nd of March, Point72 Asset Management purchased 5.3 million Curis Inc (CRIS) shares for $68 million at an average price of $12.77 per share. Shares of Curis Inc are down...
Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Utilities, Healthcare and Basic Materials sectors led shares lower. At the close in NYSE, the...
Shares of Miragen Therapeutics, Inc. (NASDAQ:MGEN) surged 20.7% after the company reported positive data from its continuing Phase 1 trial of cobomarsen in adult t-cell...
Signal Genetics, Inc. (NASDAQ:MGEN) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have...
Post the 2016 debacle, the biotech space raised hopes with growing stability this year. However, the sector has been witnessing a correction since October. It has lost 10.4% so far...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Strong Sell | Sell | Strong Sell | Strong Sell | Sell |
| Summary | Strong Sell | Sell | Strong Sell | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 146.06 | 148.82 | 145.76 | -2.73 | -1.83% | 124.93M | NASDAQ | |||
| 2,816.00 | 2,869.00 | 2,809.40 | -56.2 | -1.96% | 2.49M | NASDAQ | |||
| 364.72 | 371.41 | 361.59 | -8.34 | -2.24% | 25.87M | NASDAQ | |||
| 117.70 | 118.74 | 117.29 | -1.23 | -1.03% | 3.97M | NYSE | |||
| 9.30 | 9.57 | 9.09 | +0.17 | +1.86% | 1.74M | NASDAQ | |||
| 43.89 | 44.46 | 43.31 | -0.58 | -1.30% | 54.77M | NYSE | |||
| 22.85 | 22.99 | 22.72 | -0.24 | -1.04% | 7.99M | NYSE | |||
| 219.00 | 223.21 | 218.30 | -3.42 | -1.54% | 28.51M | NASDAQ | |||
| 215.75 | 219.45 | 215.40 | -2.62 | -1.20% | 591.02K | NYSE | |||
| 101.28 | 101.67 | 99.85 | +1.03 | +1.03% | 3.10M | NYSE | |||
| 135.23 | 135.92 | 135.05 | -1.20 | -0.88% | 5.58M | NYSE | |||
| 430.05 | 442.00 | 406.87 | -10.60 | -2.41% | 30.54M | NASDAQ | |||
| 232.74 | 237.96 | 230.27 | -2.74 | -1.16% | 426.25K | NYSE | |||
| 46.40 | 46.49 | 44.55 | +1.10 | +2.43% | 1.20M | NASDAQ | |||
| 2.41 | 2.41 | 2.30 | +0.0400 | +1.69% | 972.02K | NASDAQ |
Viridian Therapeutics, Inc., formerly Miragen Therapeutics, Inc., is a biotechnology company. The Company is engaged in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Its lead candidate, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody (mAb) that is under development for thyroid eye disease (TED). The Company's TED pipeline also includes VRDN-002 and VRDN-003. Its other programs include VRDN-004, which is under development for undisclosed rare orphan disease, and VRDN-005, which is under development for tick-borne disease (TBD). The Company also out licenses its programs.